Formosa Pharmaceuticals and Almac Discovery announce licensing agreement for ALM-401, a first-in-class Bispecific ADC targeting EGFR/ROR1 for the treatment of solid tumors

CAR-T Digest - August 2020

Weekly Digest - May 2025

06 May 2025: Formosa Pharmaceuticals and Almac Discovery announce licensing agreement for ALM-401, a first-in-class Bispecific ADC targeting EGFR/ROR1 for the treatment of solid tumors

Formosa Pharmaceuticals has secured exclusive global commercialization rights for ALM-401, a bispecific antibody drug conjugate (ADC) targeting EGFR and ROR1 in solid tumors, through a licensing agreement with Almac Discovery
LM-401 is a first-in-class ADC using a novel single-chain bispecific antibody design, which may enhance tumor penetration, epitope engagement, and simplify manufacturing
The drug has shown sustained tumor regression and a strong bystander effect in multiple solid tumor models, including non-small cell lung cancer
The licensing deal includes upfront and milestone payments, as well as future considerations tied to drug approval and commercialization stages
Formosa Pharmaceuticals sees ALM-401 as a strategic addition to its oncology pipeline and aims to collaborate with Almac Discovery on its clinical development and global launch